88 related articles for article (PubMed ID: 28648558)
1. Potential drug targets in small-bowel adenocarcinoma.
Gilbert JA
Lancet Oncol; 2017 Aug; 18(8):e436. PubMed ID: 28648558
[No Abstract] [Full Text] [Related]
2. [I. Chemotherapy for Small Bowel Adenocarcinoma].
Horimatsu T; Funakoshi T; Muto M
Gan To Kagaku Ryoho; 2018 Nov; 45(11):1589-1593. PubMed ID: 30449844
[No Abstract] [Full Text] [Related]
3. Beyond bevacizumab: a review of targeted agents in metastatic small bowel adenocarcinoma.
Sacdalan DB; Mendoza MJ; Vergara JP; Catedral LI; Ting FI; Leones LM; Berba CM; Sacdalan DL
Med Oncol; 2020 Nov; 37(11):106. PubMed ID: 33135102
[TBL] [Abstract][Full Text] [Related]
4. Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives.
Zaaimi Y; Aparicio T; Laurent-Puig P; Taieb J; Zaanan A
Clin Res Hepatol Gastroenterol; 2016 Apr; 40(2):154-60. PubMed ID: 26547136
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
[TBL] [Abstract][Full Text] [Related]
6. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.
Matboli M; El-Nakeep S; Hossam N; Habieb A; Azazy AE; Ebrahim AE; Nagy Z; Abdel-Rahman O
World J Gastroenterol; 2016 Jul; 22(26):5896-908. PubMed ID: 27468184
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a new small bowel adenocarcinoma cell line and screening of anti-cancer drug against small bowel adenocarcinoma.
Suzuki H; Hirata Y; Suzuki N; Ihara S; Sakitani K; Kobayashi Y; Kinoshita H; Hayakawa Y; Yamada A; Watabe H; Tateishi K; Ikenoue T; Yamaji Y; Koike K
Am J Pathol; 2015 Feb; 185(2):550-62. PubMed ID: 25478808
[TBL] [Abstract][Full Text] [Related]
8. Delivering on the promise of precision cancer medicine.
Berger MF; Van Allen EM
Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
[No Abstract] [Full Text] [Related]
9. New biomarkers and therapeutics can be discovered during COPD-lung cancer transition.
Wang X
Cell Biol Toxicol; 2016 Oct; 32(5):359-61. PubMed ID: 27405768
[No Abstract] [Full Text] [Related]
10. [Molecular-targeted therapy for prostate cancer].
Miyake H; Fujisawa M
Nihon Rinsho; 2016 Jan; 74(1):2-5. PubMed ID: 26793871
[No Abstract] [Full Text] [Related]
11. New developments on targeted cancer therapy: Multi-faceted issues in targeted cancer therapy.
Bao J; Qiao L
Cancer Lett; 2017 Feb; 387():1-2. PubMed ID: 28038727
[No Abstract] [Full Text] [Related]
12. Management of advanced gastric cancer.
Price TJ; Shapiro JD; Segelov E; Karapetis CS; Pavlakis N; Van Cutsem E; Shah MA; Kang YK; Tebbutt NC
Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):199-208; quiz 209. PubMed ID: 22375525
[TBL] [Abstract][Full Text] [Related]
13. Recent applications of chemosensitivity tests for colorectal cancer treatment.
Yoon YS; Kim JC
World J Gastroenterol; 2014 Nov; 20(44):16398-408. PubMed ID: 25469008
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?
Raymond E; García-Carbonero R; Wiedenmann B; Grande E; Pavel M
Cancer Metastasis Rev; 2014 Mar; 33(1):367-72. PubMed ID: 24375390
[TBL] [Abstract][Full Text] [Related]
15. The role of defective mismatch repair in small bowel adenocarcinoma in celiac disease.
Potter DD; Murray JA; Donohue JH; Burgart LJ; Nagorney DM; van Heerden JA; Plevak MF; Zinsmeister AR; Thibodeau SN
Cancer Res; 2004 Oct; 64(19):7073-7. PubMed ID: 15466202
[TBL] [Abstract][Full Text] [Related]
16. [Sensitivity testing of malignant human tumors against cytostatic agents. II].
Mattern J; Kaufmann M; Volm M; Schütze U; Wayss K; Goerttler K; Tasca C
Klin Wochenschr; 1972 Feb; 50(4):196-8. PubMed ID: 5011552
[No Abstract] [Full Text] [Related]
17. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
[No Abstract] [Full Text] [Related]
18. Mutational subgroups for oesophageal adenocarcinoma.
Burki TK
Lancet Oncol; 2016 Oct; 17(10):e426. PubMed ID: 27641478
[No Abstract] [Full Text] [Related]
19. MKK3 as oncotarget.
Bossi G
Aging (Albany NY); 2016 Jan; 8(1):1-2. PubMed ID: 26805700
[No Abstract] [Full Text] [Related]
20. Update on metastatic gastric and esophageal cancers.
Shah MA
J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
